Aya Abrahamov

2.5k total citations
68 papers, 1.9k citations indexed

About

Aya Abrahamov is a scholar working on Physiology, Cell Biology and Epidemiology. According to data from OpenAlex, Aya Abrahamov has authored 68 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Physiology, 21 papers in Cell Biology and 20 papers in Epidemiology. Recurrent topics in Aya Abrahamov's work include Lysosomal Storage Disorders Research (47 papers), Cellular transport and secretion (21 papers) and Trypanosoma species research and implications (18 papers). Aya Abrahamov is often cited by papers focused on Lysosomal Storage Disorders Research (47 papers), Cellular transport and secretion (21 papers) and Trypanosoma species research and implications (18 papers). Aya Abrahamov collaborates with scholars based in Israel, United States and South Africa. Aya Abrahamov's co-authors include Deborah Elstein, Ari Zimran, Ari Zimran, Irith Hadas‐Halpern, Raphael Mechoulam, Mia Horowitz, Orit Neudorfer, Nir Giladi, E Aghai and Bruno Bembi and has published in prestigious journals such as The Lancet, Blood and European Respiratory Journal.

In The Last Decade

Aya Abrahamov

67 papers receiving 1.9k citations

Peers

Countries citing papers authored by Aya Abrahamov

Since Specialization

Citations

This map shows the geographic impact of Aya Abrahamov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aya Abrahamov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aya Abrahamov more than expected).

Fields of papers citing papers by Aya Abrahamov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aya Abrahamov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aya Abrahamov. The network helps show where Aya Abrahamov may publish in the future.

Co-authorship network of co-authors of Aya Abrahamov

This figure shows the co-authorship network connecting the top 25 collaborators of Aya Abrahamov. A scholar is included among the top collaborators of Aya Abrahamov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aya Abrahamov. Aya Abrahamov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase 2016 ·Blood Cells Molecules and Diseases ·Ari Zimran, (unknown), Aya Abrahamov, Peter A. Cooper, (unknown), Pilar Giraldo, Мilan Petakov, Ee Shien Tan, Raul Chertkoff	27
2	Children with type 1 Gaucher disease: Changing profiles in the 21st century 2016 ·Blood Cells Molecules and Diseases ·Deborah Elstein, Gheona Altarescu, Aya Abrahamov, Ari Zimran	8
3	13,845 home therapy infusions with velaglucerase alfa exemplify safety of velaglucerase alfa and increased compliance to every-other-week intravenous enzyme replacement therapy for Gaucher disease 2015 ·Blood Cells Molecules and Diseases ·Deborah Elstein, Aya Abrahamov, (unknown), (unknown), Hagit Baris, Ari Zimran	12
4	Long-term safety and efficacy of taliglucerase alfa in pediatric patients with Gaucher disease who were treatment-naïve previously treated with immiglucerase 2015 ·Molecular Genetics and Metabolism ·Ari Zimran, (unknown), Aya Abrahamov, Peter A. Cooper, (unknown), Alona Paz, Einat Brill‐Almon, Raul Chertkoff	1
5	Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: Early Access Program results from Jerusalem 2011 ·Blood Cells Molecules and Diseases ·Deborah Elstein, Gheona Altarescu, (unknown), Mici Phillips, Aya Abrahamov, Irith Hadas‐Halpern, (unknown), Ari Zimran	19
6	Phenotypic Heterogeneity in Patients with Gaucher Disease and the N370S/V394L Genotype 2005 ·Genetic Testing ·Deborah Elstein, C. Ronald Scott, Marsha Zeigler, Aya Abrahamov, Ari Zimran	7
7	N-brain natriuretic peptide: correlation with tricuspid insufficiency in Gaucher disease 2004 ·Pulmonary Pharmacology & Therapeutics ·Deborah Elstein, Amiram Nir, (unknown), Aya Abrahamov, Ari Zimran	2
8	Objectives and Methods of Iron Chelation Therapy 2003 ·Bioinorganic Chemistry and Applications ·Chaim Hershko, Aya Abrahamov, Abraham M. Konijn, W. Breuer, Ioav Cabantchik, Pensri Pootrakul, Gabriela Link	30
9	Platelet function abnormalities in Gaucher disease patients 1999 ·American Journal of Hematology ·Shmuel Gillis, Esti Hyam, Aya Abrahamov, (unknown), Ari Zimran	51
10	Effect of vitamin K1 on glucose-6-phosphate dehydrogenase deficient neonatal erythrocytes in vitro 1998 ·Archives of Disease in Childhood Fetal & Neonatal ·Michael Kaplan, Dan Waisman, Dalia Mazor, Cathy Hammerman, David A. Bader, Aya Abrahamov, Naomi Meyerstein	9
11	Ethical guidelines for enzyme therapy in neuronopathic Gaucher disease. 1997 ·PubMed ·Deborah Elstein, Arthur G. Steinberg, Aya Abrahamov, Ari Zimran	2
12	Accuracy of ultrasonography in assessing spleen and liver size in patients with Gaucher disease: comparison to computed tomographic measurements 1997 ·Journal of Ultrasound in Medicine ·Deborah Elstein, Irith Hadas‐Halpern, (unknown), Aya Abrahamov, (unknown), Ari Zimran	63
13	Pulmonary function abnormalities in type I Gaucher disease 1996 ·European Respiratory Journal ·Eitan Kerem, Deborah Elstein, Aya Abrahamov, Yehiel Ziv, Irith Hadas‐Halpern, E Melzer, (unknown), David Branski, Ari Zimran	52
14	An efficient new cannabinoid antiemetic in pediatric oncology 1995 ·Life Sciences ·Aya Abrahamov, (unknown), Raphael Mechoulam	143
15	Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype 1995 ·The Lancet ·Aya Abrahamov, Deborah Elstein, Ari Zimran, Benjamin A. Farber, (unknown), Varda Gross‐Tsur, Irit Hadas-Halpern, Shira Ronen, Mia Horowitz, (unknown)	147
16	Adult-type Gaucher disease in children: genetics, clinical features and enzyme replacement therapy. 1993 ·PubMed ·Shoshana Zevin, Aya Abrahamov, Irith Hadas‐Halpern, (unknown), Ephrat Levy‐Lahad, Mia Horowitz, Ari Zimran	39
17	Correction of neutrophil chemotaxis defect in patients with gaucher disease by low‐dose enzyme replacement therapy 1993 ·American Journal of Hematology ·Ari Zimran, Aya Abrahamov, M Aker, Yaacov Matzner	26
18	Low‐dose high‐frequency enzyme replacement therapy for very young children with severe Gaucher disease 1993 ·British Journal of Haematology ·Ari Zimran, Irith Hadas‐Halpern, Shoshana Zevin, Ephrat Levy‐Lahad, Aya Abrahamov	33
19	Abnormal neutrophil chemotaxis in Gaucher disease 1993 ·British Journal of Haematology ·M Aker, Ari Zimran, Aya Abrahamov, Mia Horowitz, Yaacov Matzner	36
20	Hemoglobin H Disease, Alpha- and Beta-Thalassemia Traits in a Family of Kurdish Jews. 1966 ·(unknown), A Horowitz, Aya Abrahamov, C. I. Levene	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact